Most large-scale cohorts rely on static baseline measures, limiting insight into the dynamic progression of non-communicable diseases. The Kailuan Study, embedded within an industrial community in Tangshan, China, was designed to fill this gap through rolling enrollment, repeated biennial assessments, and linkage to comprehensive healthcare and insurance systems.
Since its inception, the cohort has grown from 101,510 to over 170,000 participants, capturing more than 22,000 cardiovascular events, 8,000 cancers, and 24,000 deaths by December 2023. Key findings have mapped the temporal sequence from metabolic dysfunction to clinical disease, established obesity as an independent risk factor for cardiac conduction block, and demonstrated that early-onset diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) markedly increase long-term risk. The study also evaluated real-world effectiveness of workplace-based hypertension management and statin therapy, with evidence cited in over 160 international clinical guidelines.
The Kailuan Study offers a robust framework for life-course epidemiology and multimorbidity research. Its integration of multi-omics, advanced imaging, and artificial intelligence-driven analytics positions it to develop comprehensive health management models. For clinicians and policymakers, this cohort delivers actionable evidence that prevention strategies must begin early, address dynamic risk trajectories, and be tailored to specific populations and settings.
The work titled “Cohort Profile: the Kailuan Study”, was published on Cardiac Research (accepted on May. 25, 2026).
DOI:10.1097/re9.0000000000000021